Hereditary Angioedema

News Hereditary Angioedema

• CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema

  CSL Behring announced that it has initiated an international phase I/II study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with hereditary angioedema (HAE). Part of the COMPACT (Clinical Studies for Optimal Management in Preventing Angioedem more

• Pharming announces extension of their license agreement for the commercialisation of Ruconest

  Biotech company Pharming Group NV announced that they have agreed an extension of their existing agreement with Swedish Orphan Biovitrum to include new territories in the Balkans, North Africa and the Middle East for the commercialization of Ruconest® (recombinant human C1 inhibitor) for the treatme more

• Dyax Announces Treatment of First Patient in Phase 2 Trial of Ecallantide for ACE Inhibitor-Induced Angioedema

  Dyax Corp. announced treatment of the first patient in a Phase 2 trial evaluating the efficacy and safety of ecallantide, a potent, selective, reversible inhibitor of plasma kallikrein, for acute treatment of angiotensin converting enzyme (ACE) inhibitor-induced angioedema. This form of angioedema, more

Publications Hereditary Angioedema

• Therapeutic management of hereditary angioedema due to C1 inhibitor deficiency

  Hereditary angioedema (HAE) due to C1 inhibitor (C1-INH) deficiency is a rare genetic disease characterized by recurrent swellings of the subcutaneous and submucosal tissues that can manifest as cutaneous edema, abdominal pain and laryngeal edema with airway obstruction. These symptoms have a signif more

• Population pharmacokinetics of recombinant human C1‐inhibitor in patients with hereditary angioedema

  Structured Abstract Aim To characterise the PK of rhC1INH in healthy volunteers and HAE patients. Methods C1INH plasma levels following 294 administrations of rhC1INH in 133 subjects were fitted using nonlinear mixed‐effects modelling. The model was used to simulate maximal C1INH levels more

• Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial

  Bradykinin is the key mediator of symptoms of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of edema of the skin, mucosa and muscle. Icatibant, a bradykinin B2 receptor antagonist, is an effective and generally well-tolerated treatment option for acute atta more

Market studies Hereditary Angioedema

• Hereditary Angioedema Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Hereditary Angioedema Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Hereditary Angioedema Therapeutics market. The more

• Hereditary Angioedema (HAE) – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Hereditary Angioedema (HAE) - Pipeline Review, H1 2012', provides an overview of the Hereditary Angioedema (HAE) therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest update more

• Hereditary Angioedema (HAE) - Pipeline Review, Q2 2011

  Introduction Global Markets Direct’s, 'Hereditary Angioedema (HAE) - Pipeline Review, Q2 2011', provides an overview of the Hereditary Angioedema (HAE) therapeutic pipeline. This report provides information on the therapeutic development for Hereditary Angioedema (HAE), complete with latest updates more

Websites Hereditary Angioedema